OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients.

A functional polymorphism rs1799971 (A118G) in the μ-opioid receptor gene (OPRM1) produces an amino acid substitution Asn40Asp, which is believed to influence naltrexone response in nondepressed alcohol-dependent patients. In this study, patients with alcohol dependence and major depression (n=108) received open-label naltrexone and clinical case management for 12 weeks, and were randomized to citalopram or placebo. General linear mixed models examined the effect of the OPRM1 A118G genotype on alcohol outcomes during treatment. There was no evidence of any difference in the percentage of days abstinent, drinks per drinking day or percentage of heavy drinking days between Asp40 carriers and noncarriers during treatment. This study therefore failed to replicate the previous positive findings for this single nucleotide polymorphism in relation to naltrexone response, possibly indicating that the effect is not present in depressed patients.

[1]  Jason M. White,et al.  OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence , 2011, Pharmacogenetics and genomics.

[2]  G. Jenkins,et al.  Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. , 2010, The American journal of psychiatry.

[3]  D. Couper,et al.  OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. , 2009, Alcoholism, clinical and experimental research.

[4]  D. Couper,et al.  An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. , 2008, Archives of general psychiatry.

[5]  L. Ray,et al.  Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. , 2007, Archives of general psychiatry.

[6]  R. Rosenheck,et al.  Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. , 2007, Alcoholism, clinical and experimental research.

[7]  Robert A Koeppe,et al.  Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. , 2006, Archives of general psychiatry.

[8]  R. Feinn,et al.  Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. , 2006, Drug and alcohol dependence.

[9]  D. Oslin,et al.  A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients , 2003, Neuropsychopharmacology.

[10]  J A Tischfield,et al.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Oslin,et al.  A mu opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients , 2008, Psychopharmacology.

[12]  D. Oslin,et al.  A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. , 2003, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.